BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Malaguarnera M, Bella R, Vacante M, Giordano M, Malaguarnera G, Gargante MP, Motta M, Mistretta A, Rampello L, Pennisi G. Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy. Scand J Gastroenterol. 2011;46:750-759. [PMID: 21443422 DOI: 10.3109/00365521.2011.565067] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 4.9] [Reference Citation Analysis]
Number Citing Articles
1 Malaguarnera M, Vacante M, Motta M, Giordano M, Malaguarnera G, Bella R, Nunnari G, Rampello L, Pennisi G. Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial. Metab Brain Dis 2011;26:281-9. [DOI: 10.1007/s11011-011-9260-z] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
2 Yousefi Rad E, Eslampour E, Falahi E, Mardani M, Hekmatdoost A, Asbaghi O, Saboori S. Effects of carnitine supplementation on liver aminotransferase enzymes: A systematic review and meta-analysis of randomized controlled clinical trials. Indian J Gastroenterol 2019;38:470-9. [PMID: 31828538 DOI: 10.1007/s12664-019-00983-2] [Reference Citation Analysis]
3 Veronese N, Stubbs B, Solmi M, Ajnakina O, Carvalho AF, Maggi S. Acetyl-l-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis. Psychosom Med 2018;80:154-9. [DOI: 10.1097/psy.0000000000000537] [Cited by in Crossref: 26] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
4 Sturgeon JP, Shawcross DL. Recent insights into the pathogenesis of hepatic encephalopathy and treatments. Expert Rev Gastroenterol Hepatol. 2014;8:83-100. [PMID: 24236755 DOI: 10.1586/17474124.2014.858598] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
5 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications. Clin Mol Hepatol 2020;26:83-127. [PMID: 31918536 DOI: 10.3350/cmh.2019.0010n] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
6 Rama Rao KV, Norenberg MD. Brain energy metabolism and mitochondrial dysfunction in acute and chronic hepatic encephalopathy. Neurochem Int. 2012;60:697-706. [PMID: 21989389 DOI: 10.1016/j.neuint.2011.09.007] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 5.4] [Reference Citation Analysis]
7 Maldonado C, Guevara N, Queijo C, González R, Fagiolino P, Vázquez M. Carnitine and/or Acetylcarnitine Deficiency as a Cause of Higher Levels of Ammonia. Biomed Res Int 2016;2016:2920108. [PMID: 26998483 DOI: 10.1155/2016/2920108] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
8 Gao X, Liang M, Fang Y, Zhao F, Tian J, Zhang X, Qin X. Deciphering the Differential Effective and Toxic Responses of Bupleuri Radix following the Induction of Chronic Unpredictable Mild Stress and in Healthy Rats Based on Serum Metabolic Profiles. Front Pharmacol 2017;8:995. [PMID: 29379441 DOI: 10.3389/fphar.2017.00995] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
9 Hassan A, Tsuda Y, Asai A, Yokohama K, Nakamura K, Sujishi T, Ohama H, Tsuchimoto Y, Fukunishi S, Abdelaal UM, Arafa UA, Hassan AT, Kassem AM, Higuchi K. Effects of Oral L-Carnitine on Liver Functions after Transarterial Chemoembolization in Intermediate-Stage HCC Patients. Mediators Inflamm 2015;2015:608216. [PMID: 26664151 DOI: 10.1155/2015/608216] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
10 Mahpour NY, Pioppo-Phelan L, Reja M, Tawadros A, Rustgi VK. Pharmacologic Management of Hepatic Encephalopathy. Clin Liver Dis 2020;24:231-42. [PMID: 32245530 DOI: 10.1016/j.cld.2020.01.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Martí-carvajal AJ, Gluud C, Arevalo-rodriguez I; Cochrane Hepato-Biliary Group. Acetyl-L-carnitine for patients with hepatic encephalopathy. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd011451] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
12 Jamilian M, Foroozanfard F, Kavossian E, Aghadavod E, Amirani E, Mahdavinia M, Mafi A, Asemi Z. Carnitine and chromium co-supplementation affects mental health, hormonal, inflammatory, genetic, and oxidative stress parameters in women with polycystic ovary syndrome. J Psychosom Obstet Gynaecol 2019;:1-9. [PMID: 30835597 DOI: 10.1080/0167482X.2018.1557144] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
13 Jamilian H, Jamilian M, Samimi M, Afshar Ebrahimi F, Rahimi M, Bahmani F, Aghababayan S, Kouhi M, Shahabbaspour S, Asemi Z. Oral carnitine supplementation influences mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Gynecol Endocrinol 2017;33:442-7. [PMID: 28277138 DOI: 10.1080/09513590.2017.1290071] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
14 Kocsis K, Knapp L, Gellért L, Oláh G, Kis Z, Takakuwa H, Iwamori N, Ono E, Toldi J, Farkas T. Acetyl-L-carnitine normalizes the impaired long-term potentiation and spine density in a rat model of global ischemia. Neuroscience 2014;269:265-72. [PMID: 24704513 DOI: 10.1016/j.neuroscience.2014.03.055] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
15 Rajpurohit S, Musunuri B, Shailesh, Mohan PB, Shetty S. Novel Drugs for the Management of Hepatic Encephalopathy: Still a Long Journey to Travel. Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.01.012] [Reference Citation Analysis]
16 Sato S, Namisaki T, Furukawa M, Saikawa S, Kawaratani H, Kaji K, Takaya H, Shimozato N, Sawada Y, Kitagawa K, Moriya K, Akahane T, Mitoro A, Hoki N, Ann T, Yoshiji H. Effect of L-carnitine on health-related quality of life in patients with liver cirrhosis. Biomed Rep 2020;13:65. [PMID: 33149909 DOI: 10.3892/br.2020.1372] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
17 Wang S, Han C, Lee S, Patkar AA, Masand PS, Pae C. A review of current evidence for acetyl-l-carnitine in the treatment of depression. Journal of Psychiatric Research 2014;53:30-7. [DOI: 10.1016/j.jpsychires.2014.02.005] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 7.6] [Reference Citation Analysis]
18 Filiou MD, Sandi C. Anxiety and Brain Mitochondria: A Bidirectional Crosstalk. Trends in Neurosciences 2019;42:573-88. [DOI: 10.1016/j.tins.2019.07.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
19 Martí-Carvajal AJ, Gluud C, Arevalo-Rodriguez I, Martí-Amarista CE. Acetyl-L-carnitine for patients with hepatic encephalopathy. Cochrane Database Syst Rev 2019;1:CD011451. [PMID: 30610762 DOI: 10.1002/14651858.CD011451.pub2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
20 Cai X, Wang L, Hu C. Retracted : Efficacy of different drugs in the treatment of minimal hepatic encephalopathy: A network meta‐analysis involving 826 patients based on 10 randomized controlled trials. J Cell Biochem 2018;119:8336-45. [DOI: 10.1002/jcb.26886] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
21 Hasan LZ, Wu GY. Novel Agents in the Management of Hepatic Encephalopathy: A Review. J Clin Transl Hepatol 2021;9:749-59. [PMID: 34722190 DOI: 10.14218/JCTH.2021.00102] [Reference Citation Analysis]
22 Jamshidzadeh A, Niknahad H, Heidari R, Zarei M, Ommati MM, Khodaei F. Carnosine protects brain mitochondria under hyperammonemic conditions: Relevance to hepatic encephalopathy treatment. PharmaNutrition 2017;5:58-63. [DOI: 10.1016/j.phanu.2017.02.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
23 Kaplan BJ, Rucklidge JJ, Romijn A, Mcleod K. The Emerging Field of Nutritional Mental Health: Inflammation, the Microbiome, Oxidative Stress, and Mitochondrial Function. Clinical Psychological Science 2015;3:964-80. [DOI: 10.1177/2167702614555413] [Cited by in Crossref: 72] [Cited by in F6Publishing: 24] [Article Influence: 10.3] [Reference Citation Analysis]
24 Pennisi M, Lanza G, Cantone M, D'Amico E, Fisicaro F, Puglisi V, Vinciguerra L, Bella R, Vicari E, Malaguarnera G. Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update. Nutrients 2020;12:E1389. [PMID: 32408706 DOI: 10.3390/nu12051389] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
25 Malaguarnera M. Carnitine derivatives: clinical usefulness. Curr Opin Gastroenterol 2012;28:166-76. [PMID: 22333562 DOI: 10.1097/MOG.0b013e3283505a3b] [Cited by in Crossref: 64] [Cited by in F6Publishing: 28] [Article Influence: 6.4] [Reference Citation Analysis]
26 Eftekar M. The association between hepatic encephalopathy/minimal hepatic encephalopathy and depressive and anxiety disorders: a systematic review. Australas Psychiatry 2020;28:61-5. [DOI: 10.1177/1039856219875054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
27 Alimirah M, Sadiq O, Gordon SC. Novel Therapies in Hepatic Encephalopathy. Clin Liver Dis 2020;24:303-15. [PMID: 32245535 DOI: 10.1016/j.cld.2020.01.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Pirmadah F, Ramezani-Jolfaie N, Mohammadi M, Talenezhad N, Clark CCT, Salehi-Abargouei A. Does L-carnitine supplementation affect serum levels of enzymes mainly produced by liver? A systematic review and meta-analysis of randomized controlled clinical trials. Eur J Nutr 2020;59:1767-83. [PMID: 31385062 DOI: 10.1007/s00394-019-02068-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
29 Preston G, Emmerzaal T, Kirdar F, Schrader L, Henckens M, Morava E, Kozicz T. Cerebellar mitochondrial dysfunction and concomitant multi-system fatty acid oxidation defects are sufficient to discriminate PTSD-like and resilient male mice. Brain Behav Immun Health 2020;6:100104. [PMID: 34589865 DOI: 10.1016/j.bbih.2020.100104] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Malaguarnera G, Pennisi M, Gagliano C, Vacante M, Mala-guarnera M, Salomone S, Drago F, Bertino G, Caraci F, Nunnari G. Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α 2b Plus Ribavirin: Effect on Work Performance; A Randomized Clinical Trial. Hepat Mon. 2014;14:e11608. [PMID: 24910702 DOI: 10.5812/hepatmon.11608] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
31 Colucci L, Bosco M, Rosario Ziello A, Rea R, Amenta F, Fasanaro AM. Effectiveness of nootropic drugs with cholinergic activity in treatment of cognitive deficit: a review. J Exp Pharmacol 2012;4:163-72. [PMID: 27186129 DOI: 10.2147/JEP.S35326] [Cited by in Crossref: 23] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
32 Niknahad H, Jamshidzadeh A, Heidari R, Zarei M, Ommati MM. Ammonia-induced mitochondrial dysfunction and energy metabolism disturbances in isolated brain and liver mitochondria, and the effect of taurine administration: relevance to hepatic encephalopathy treatment. Clin Exp Hepatol 2017;3:141-51. [PMID: 29062904 DOI: 10.5114/ceh.2017.68833] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
33 Kou L, Sun R, Ganapathy V, Yao Q, Chen R. Recent advances in drug delivery via the organic cation/carnitine transporter 2 (OCTN2/SLC22A5). Expert Opin Ther Targets 2018;22:715-26. [PMID: 30016594 DOI: 10.1080/14728222.2018.1502273] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
34 Amodio P. Hepatic encephalopathy. In: Lee SS, Moreau R, editors. Cirrhosis: A practical guide to management. Chichester: John Wiley & Sons, Ltd; 2015. pp. 105-23. [DOI: 10.1002/9781118412640.ch11] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Kocsis K, Knapp L, Mészáros J, Kis Z, Farkas T, Vécsei L, Toldi J. Acetyl-L-carnitine and oxaloacetate in post-treatment against LTP impairment in a rat ischemia model. An in vitro electrophysiological study. J Neural Transm (Vienna) 2015;122:867-72. [PMID: 25432433 DOI: 10.1007/s00702-014-1343-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
36 Cuturic M, Abramson RK, Moran RR, Hardin JW, Frank EM, Sellers AA. Serum carnitine levels and levocarnitine supplementation in institutionalized Huntington’s disease patients. Neurol Sci. 2013;34:93-98. [PMID: 22294053 DOI: 10.1007/s10072-012-0952-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
37 Bianchi G, Giovagnoli M, Sasdelli AS, Marchesini G. Hepatic encephalopathy and health-related quality of life. Clin Liver Dis 2012;16:159-70. [PMID: 22321471 DOI: 10.1016/j.cld.2011.12.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
38 Frontera JA. Management of hepatic encephalopathy. Curr Treat Options Neurol. 2014;16:297. [PMID: 24807164 DOI: 10.1007/s11940-014-0297-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
39 Ridola L, Nardelli S, Gioia S, Riggio O. Quality of life in patients with minimal hepatic encephalopathy. World J Gastroenterol 2018; 24(48): 5446-5453 [PMID: 30622374 DOI: 10.3748/wjg.v24.i48.5446] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
40 Smeland OB, Meisingset TW, Borges K, Sonnewald U. Chronic acetyl-L-carnitine alters brain energy metabolism and increases noradrenaline and serotonin content in healthy mice. Neurochem Int 2012;61:100-7. [PMID: 22549035 DOI: 10.1016/j.neuint.2012.04.008] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
41 Anikin GS, Makhova AA, Shikh EV. [Prospects of application of acetyl-L-carnitine in neurology and psychiatry (the treatment of polyneuropathy and depressive states)]. Zh Nevrol Psikhiatr Im S S Korsakova 2019;119:130-5. [PMID: 31626181 DOI: 10.17116/jnevro2019119081130] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Pennisi M, Lanza G, Cantone M, D'Amico E, Fisicaro F, Puglisi V, Vinciguerra L, Bella R, Vicari E, Malaguarnera G. Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update. Nutrients 2020;12:E1389. [PMID: 32408706 DOI: 10.3390/nu12051389] [Reference Citation Analysis]
43 Kronsten VT, Shawcross DL. Hepatic encephalopathy and depression in chronic liver disease: is the common link systemic inflammation? Anal Biochem 2021;:114437. [PMID: 34715068 DOI: 10.1016/j.ab.2021.114437] [Reference Citation Analysis]
44 Hashimoto JG, Wiren KM, Wilhelm CJ. A neurotoxic alcohol exposure paradigm does not induce hepatic encephalopathy. Neurotoxicol Teratol 2016;56:35-40. [PMID: 27268733 DOI: 10.1016/j.ntt.2016.06.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
45 Ringseis R, Keller J, Eder K. Mechanisms underlying the anti-wasting effect of l-carnitine supplementation under pathologic conditions: evidence from experimental and clinical studies. Eur J Nutr 2013;52:1421-42. [DOI: 10.1007/s00394-013-0511-0] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
46 Malaguarnera G, Pennisi M, Bertino G, Motta M, Borzì AM, Vicari E, Bella R, Drago F, Malaguarnera M. Resveratrol in Patients with Minimal Hepatic Encephalopathy. Nutrients 2018;10:E329. [PMID: 29522439 DOI: 10.3390/nu10030329] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
47 Wang P, Gao X, Liang M, Fang Y, Jia J, Tian J, Li Z, Qin X. Dose-Effect/Toxicity of Bupleuri Radix on Chronic Unpredictable Mild Stress and Normal Rats Based on Liver Metabolomics. Front Pharmacol 2021;12:627451. [PMID: 34557088 DOI: 10.3389/fphar.2021.627451] [Reference Citation Analysis]
48 Hadjihambi A, Khetan V, Jalan R. Pharmacotherapy for hyperammonemia. Expert Opin Pharmacother 2014;15:1685-95. [PMID: 25032885 DOI: 10.1517/14656566.2014.931372] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
49 Mescka CP, Guerreiro G, Donida B, Marchetti D, Wayhs CA, Ribas GS, Coitinho AS, Wajner M, Dutra-Filho CS, Vargas CR. Investigation of inflammatory profile in MSUD patients: benefit of L-carnitine supplementation. Metab Brain Dis 2015;30:1167-74. [PMID: 26002427 DOI: 10.1007/s11011-015-9686-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
50 Burkard T, Biedermann A, Herold C, Dietlein M, Rauch M, Diefenbach M. Treatment with a potassium-iron-phosphate-citrate complex improves PSE scores and quality of life in patients with minimal hepatic encephalopathy: a multicenter, randomized, placebo-controlled, double-blind clinical trial. Eur J Gastroenterol Hepatol. 2013;25:352-358. [PMID: 23117470 DOI: 10.1097/MEG.0b013e32835afaa5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
51 Jiang Q, Jiang G, Shi K, Cai H, Wang Y, Zheng M. Oral Acetyl-L-Carnitine treatment in hepatic encephalopathy: view of evidence-based medicine. Annals of Hepatology 2013;12:803-9. [DOI: 10.1016/s1665-2681(19)31323-7] [Cited by in Crossref: 24] [Article Influence: 2.7] [Reference Citation Analysis]
52 Liu X, Zheng P, Zhao X, Zhang Y, Hu C, Li J, Zhao J, Zhou J, Xie P, Xu G. Discovery and Validation of Plasma Biomarkers for Major Depressive Disorder Classification Based on Liquid Chromatography–Mass Spectrometry. J Proteome Res 2015;14:2322-30. [DOI: 10.1021/acs.jproteome.5b00144] [Cited by in Crossref: 98] [Cited by in F6Publishing: 92] [Article Influence: 14.0] [Reference Citation Analysis]
53 Askarpour M, Djafarian K, Ghaedi E, Sadeghi O, Sheikhi A, Shab-bidar S. Effect of L-Carnitine Supplementation on Liver Enzymes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Archives of Medical Research 2020;51:82-94. [DOI: 10.1016/j.arcmed.2019.12.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Kronsten VT, Tranah TH, Pariante C, Shawcross DL. Gut-derived systemic inflammation as a driver of depression in chronic liver disease. J Hepatol 2021:S0168-8278(21)02180-2. [PMID: 34800610 DOI: 10.1016/j.jhep.2021.11.008] [Reference Citation Analysis]
55 Malaguarnera M. Acetyl-L-carnitine in hepatic encephalopathy. Metab Brain Dis 2013;28:193-9. [DOI: 10.1007/s11011-013-9376-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]